Business
IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1
Positions IGC at the intersection of biotech innovation and cannabinoid science in one of the largest unmet medical needs in the world Alzheimer's affects over 50 million people globally, with more than 400 million at risk from underlying disease ...
About this update from Igc Pharma, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Positions IGC at the intersection of biotech innovation and cannabinoid science in one of the largest unmet medical needs in the world","length":134,"tagName":"p"}]},{"val":[{"type":"text","content":"Alzheimer's affects over 50 million people globally, with more than 400 million at risk from underlying disease pathology","length":125,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":259,"olType":false},{"type":"text","content":"POTOMAC, MARYLAND / ACCESS Newswire / August 12, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced promising preclinical results for IGC-M3, a novel small molecule designed to address multiple biological drivers of Alzheimer's disease. IGC-M3 demonstrated activity in laboratory models against beta-amyloid aggregation, oxidative stress, mitochondrial dysfunction, and neuroinflammation, four key contributors to Alzheimer's pathology.","length":498,"tagName":"p"},{"type":"text","content":"The findings underscore IGC Pharma's dual-pronged strategy in Alzheimer's disease, which includes:","length":106,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"IGC-AD1 - A proprietary, cannabinoid-based formulation currently in Phase 2 clinical trials for agitation in Alzheimer's disease, with potential disease-modifying effects under investigation.","length":195,"tagName":"p"}]},{"val":[{"type":"text","content":"IGC-M3 - A multifunctional, next-generation small molecule with the potential to impact multiple disease mechanisms, currently in preclinical development.","length":154,"tagName":"p"}]}],"tagName":"ol","bulletedList":false,"length":349},{"type":"text","content":""Few companies in the Alzheimer's space are advancing both a late-stage cannabinoid-based therapy and an early-stage small molecule with multi-pathway potential," said Ram Mukunda, CEO of IGC Pharma. "IGC-AD1 offers a near-term opportunity to address agitation, a debilitating symptom affecting up to 76% of Alzheimer's patients using a combination of two actives one of which is low doses of Δ9-tetrahydrocannabinol ("THC"), a naturally extracted cannabinoid, while IGC-M3 expands our reach further into disease modification. Together, they position IGC as a differentiated player in ...